Boston Scientific Co. (NYSE:BSX) EVP David A. Pierce sold 1,650 shares of Boston Scientific stock in a transaction dated Thursday, June 7th. The stock was sold at an average price of $30.83, for a total value of $50,869.50. The transaction was disclosed in a filing with the SEC, which is available at this link.
Shares of Boston Scientific traded up $0.61, reaching $32.34, during midday trading on Thursday, according to Marketbeat.com. The company’s stock had a trading volume of 208,156 shares, compared to its average volume of 8,243,987. The company has a current ratio of 0.82, a quick ratio of 0.59 and a debt-to-equity ratio of 0.68. Boston Scientific Co. has a fifty-two week low of $24.54 and a fifty-two week high of $37.30. The company has a market cap of $47.36 billion, a price-to-earnings ratio of 25.65, a PEG ratio of 2.45 and a beta of 0.77.
Boston Scientific (NYSE:BSX) last released its quarterly earnings results on Wednesday, April 25th. The medical equipment provider reported $0.33 earnings per share for the quarter, beating analysts’ consensus estimates of $0.32 by $0.01. Boston Scientific had a net margin of 1.21% and a return on equity of 25.10%. The company had revenue of $2.38 billion during the quarter, compared to the consensus estimate of $2.34 billion. During the same period in the previous year, the business earned $0.29 earnings per share. The firm’s quarterly revenue was up 10.1% on a year-over-year basis. equities research analysts forecast that Boston Scientific Co. will post 1.39 earnings per share for the current year.
A number of equities analysts recently commented on the company. ValuEngine upgraded Boston Scientific from a “hold” rating to a “buy” rating in a report on Monday. Argus lifted their price target on Boston Scientific from $32.00 to $36.00 and gave the stock a “buy” rating in a report on Thursday, June 7th. Zacks Investment Research upgraded Boston Scientific from a “hold” rating to a “buy” rating and set a $34.00 price target for the company in a report on Monday, May 21st. TheStreet upgraded Boston Scientific from a “c” rating to an “a-” rating in a report on Tuesday, May 29th. Finally, Jefferies Financial Group reiterated a “hold” rating and set a $31.00 price target on shares of Boston Scientific in a report on Thursday, April 26th. One analyst has rated the stock with a sell rating, three have given a hold rating, eighteen have assigned a buy rating and three have given a strong buy rating to the company’s stock. The stock has an average rating of “Buy” and an average price target of $32.39.
About Boston Scientific
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: Cardiovascular, Rhythm Management, and MedSurg. The company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions therapy products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as certain peripheral vessels; and structural heart therapy systems.
Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.